- Home
- BANX vs VTYX Comparison
BANX vs VTYX Comparison
Compare BANX & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- VTYX
- Stock Information
- Founded
- BANX 2013
- VTYX 2018
- Country
- BANX United States
- VTYX United States
- Employees
- BANX N/A
- VTYX N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- BANX Finance
- VTYX Health Care
- Exchange
- BANX Nasdaq
- VTYX Nasdaq
- Market Cap
- BANX 149.0M
- VTYX 154.9M
- IPO Year
- BANX N/A
- VTYX 2021
- Fundamental
- Price
- BANX $21.08
- VTYX $1.41
- Analyst Decision
- BANX
- VTYX Buy
- Analyst Count
- BANX 0
- VTYX 4
- Target Price
- BANX N/A
- VTYX $11.33
- AVG Volume (30 Days)
- BANX 18.7K
- VTYX 775.9K
- Earning Date
- BANX 03-25-2025
- VTYX 02-27-2025
- Dividend Yield
- BANX 10.04%
- VTYX N/A
- EPS Growth
- BANX N/A
- VTYX N/A
- EPS
- BANX 2.35
- VTYX N/A
- Revenue
- BANX $29,467,794.00
- VTYX N/A
- Revenue This Year
- BANX N/A
- VTYX N/A
- Revenue Next Year
- BANX N/A
- VTYX N/A
- P/E Ratio
- BANX $8.90
- VTYX N/A
- Revenue Growth
- BANX 2.74
- VTYX N/A
- 52 Week Low
- BANX $17.91
- VTYX $1.34
- 52 Week High
- BANX $21.67
- VTYX $8.12
- Technical
- Relative Strength Index (RSI)
- BANX 49.56
- VTYX 36.94
- Support Level
- BANX $20.80
- VTYX $1.36
- Resistance Level
- BANX $21.31
- VTYX $1.50
- Average True Range (ATR)
- BANX 0.26
- VTYX 0.11
- MACD
- BANX -0.01
- VTYX 0.01
- Stochastic Oscillator
- BANX 51.85
- VTYX 25.45
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds, and others.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.